BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $106.00

Posted by Francis Steltz on Aug 12th, 2026

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its target price raised by equities research analysts at Canaccord Genuity Group from $104.00 to $106.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 25.97% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Mizuho decreased their price target on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the company an “overweight” rating in a research note on Tuesday. HC Wainwright upped their target price on BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, July 13th. Citigroup upped their target price on BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a report on Thursday, July 16th. Finally, JPMorgan Chase & Co. raised their price target on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.53.

Get Our Latest Stock Report on BridgeBio Pharma

BridgeBio Pharma Price Performance

Shares of BBIO stock traded up $0.45 on Wednesday, hitting $84.15. 333,352 shares of the stock traded hands, compared to its average volume of 2,987,676. The company’s fifty day moving average is $76.47 and its 200 day moving average is $73.07. BridgeBio Pharma has a 1-year low of $46.81 and a 1-year high of $93.42. The company has a market capitalization of $16.45 billion, a PE ratio of -23.57 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The business had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. During the same period in the previous year, the company posted ($0.95) earnings per share. BridgeBio Pharma’s revenue for the quarter was up 120.4% compared to the same quarter last year. As a group, equities research analysts expect that BridgeBio Pharma will post -2.31 EPS for the current year.

Insider Activity at BridgeBio Pharma

In other news, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $67.15, for a total transaction of $671,500.00. Following the transaction, the director directly owned 11,589 shares of the company’s stock, valued at approximately $778,201.35. This trade represents a 46.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the sale, the chief executive officer owned 535,686 shares in the company, valued at approximately $36,137,377.56. This represents a 6.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 392,117 shares of company stock valued at $29,934,700. 14.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Brooklands Fund Management Ltd bought a new position in BridgeBio Pharma during the fourth quarter valued at about $210,348,000. Price T Rowe Associates Inc. MD raised its position in BridgeBio Pharma by 144.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after acquiring an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC raised its position in BridgeBio Pharma by 25.8% in the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after acquiring an additional 2,259,378 shares in the last quarter. Norges Bank acquired a new stake in BridgeBio Pharma in the 4th quarter valued at about $116,802,000. Finally, Wellington Management Group LLP raised its holdings in shares of BridgeBio Pharma by 130.4% in the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock worth $179,654,000 after purchasing an additional 1,329,537 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: Analysts raised price targets following the second-quarter update. JPMorgan lifted its target from $100 to $111 and maintained an “overweight” rating. Piper Sandler raised its target to $115, while TD Cowen increased its target to $110, Bank of America to $104, and Wells Fargo to $102. These targets imply substantial upside from BBIO’s recent trading level. Benzinga analyst price-target updates
Positive Sentiment: Attruby sales are accelerating sharply. Second-quarter revenue reached $243.7 million, exceeding the $220.9 million consensus estimate and rising 120.4% year over year. Attruby U.S. net sales reportedly increased 311% year over year, while ex-U.S. Beyonttra royalties grew 62% sequentially. Management reaffirmed guidance for more than $1 billion in combined 2026 Attruby and Beyonttra global sales. Q2 earnings and Attruby sales report
Positive Sentiment: Pipeline and financing developments support the growth outlook. BridgeBio expects three product launches by mid-2027, and a reported $1 billion preferred-equity raise may provide additional capital for commercial expansion and pipeline investment. BridgeBio Attruby and pipeline outlook
Neutral Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees. The grants are intended to support hiring and retention but will create limited future dilution. BridgeBio inducement grants announcement
Negative Sentiment: Profitability remains a concern. BBIO reported a second-quarter loss of $0.78 per share, wider than the roughly $0.58–$0.64 analyst estimates, despite improving from a $0.95 loss a year earlier. Continued investment and launch costs could keep earnings negative in the near term. BridgeBio second-quarter earnings report

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.